Benralizumab用于轻中度持续性哮喘的3期随机对照试验(BISE)
BISE是一项随机双盲安慰剂对照3期试验,纳入211例接受ICS治疗的轻中度持续性哮喘患者,比较Benralizumab 30 mg每4周皮下注射与安慰剂的疗效。12周时Benralizumab组支气管舒张前FEV1较基线改善70 mL,安慰剂组为0 mL,组间差异80 mL(95%CI 0-150;两组不良事件发生率相似。
要点
- 该FEV1改善未达到10%的最小临床重要差异,因此不推荐在该人群中使用Benralizumab。
- 两组不良事件发生率相似,常见为上呼吸道感染和鼻咽炎,严重不良事件罕见。
核心结论
- 在ICS治疗的轻中度持续性哮喘患者中,Benralizumab 30 mg每4周皮下注射12周对支气管舒张前FEV1的改善未达最小临床重要差异,不推荐使用。
- 研究提示接受ICS的轻中度持续性哮喘患者可能存在活跃且可干预的疾病过程,值得进一步研究。
研究设计与样本
- 随机、双盲、安慰剂对照、3期试验,在6个国家52个临床研究中心开展。
- 纳入18-75岁、体重≥40 kg、筛选时支气管舒张后FEV1可逆性≥12%、接受低至中剂量ICS或低剂量ICS+LABA、支气管舒张前FEV1占预计值>50%至90%、随机前7天内有哮喘症状的患者。
- 共筛查351例,随机211例(安慰剂105例,Benralizumab 106例),按血嗜酸性粒细胞计数(<300 vs ≥300 cells/μL)和地区(美国 vs 其他)分层,1:1随机。
- 所有患者ICS统一转换为布地奈德干粉吸入剂180 μg或200 μg每日两次,主要终点为12周时支气管舒张前FEV1较基线变化,采用意向性治疗分析。
主要发现
- 12周时Benralizumab组支气管舒张前FEV1较基线变化为70 mL(基线2248 mL [SD 606],12周2310 mL [670]),安慰剂组为0 mL(基线2246 mL [SD 768],12周2261 mL [796])。
- Benralizumab组不良事件发生44例(42%),安慰剂组49例(47%);最常见均为鼻咽炎(每组8例[8%])和上呼吸道感染(每组5例[5%])。
- 严重不良事件:Benralizumab组2例(2%)(全血细胞减少和自杀未遂,均认为与治疗无关),安慰剂组2例(2%)(宫颈癌和结肠腺瘤)。
关键数值与推荐
- 最小临床重要差异为10%,本试验未达到。
临床怎么用
- 不推荐在轻中度持续性哮喘患者中使用Benralizumab改善肺功能。
- 对于接受ICS的轻中度持续性哮喘患者,应关注可能存在的活跃可干预疾病过程,但Benralizumab不作为常规治疗选择。
局限性
- 研究仅评估12周治疗,长期疗效未知。
- 主要终点未达最小临床重要差异,统计显著性不代表临床意义。
- 研究纳入标准要求支气管舒张可逆性≥12%,可能限制结果外推。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Benralizumab is a humanised, anti-interleukin 5 receptor α monoclonal antibody that directly and rapidly depletes eosinophils, reduces asthma exacerbations, and improves lung function for patients with severe eosinophilic asthma. The objective of this trial was to assess the safety and efficacy of benralizumab for patients with mild to moderate, persistent asthma. METHODS: In this randomised, double-blind, placebo-controlled, phase 3 trial, we recruited patients aged 18-75 years, weighing at least 40 kg, and with a postbronchodilator reversibility in forced expiratory volume in 1 s (FEV1) of at least 12% at screening, from 52 clinical research centres in six countries. Patients must have been receiving either low- to medium-dosage inhaled corticosteroids (ICS) or low-dosage ICS plus long-acting β2 agonist fixed-combination therapy at screening, had a morning prebronchodilator FEV1 of more than 50% to 90% predicted at screening, and had one or more of the following symptoms within the 7 days before randomisation: a daytime or night-time asthma symptom score of at least 1 for at least 2 days, rescue short-acting β2 agonist use for at least 2 days, or night-time awakenings due to asthma for at least one night. We converted patients' ICS treatments to 180 μg or 200 μg budesonide dry powder inhaler twice daily for the entire duration of the study using the approved dosages in the patients' respective countries and randomly allocated them (1:1; stratified by blood eosinophil count [<300 cells per μL vs ≥300 cells per μL] and region [USA vs the rest of the world]) with an interactive web-based voice response system to receive subcutaneous placebo or benralizumab 30 mg injections every 4 weeks for 12 weeks. All patients and investigators involved in patient treatment or clinical assessment and those assessing outcomes were masked to treatment allocation. The primary endpoint was change from baseline prebronchodilator FEV1 at week 12. Efficacy analyses used an intention to treat approach. This trial is registered with ClinicalTrials.gov, number NCT02322775. FINDINGS: Between Feb 2, 2015, and April 24, 2015, we enrolled 351 patients, with 211 (60%) randomly assigned (105 [50%] to placebo and 106 [50%] to benralizumab). Benralizumab resulted in an 80 mL (95% CI 0-150; p=0·04) greater improvement (least-squares mean difference) in prebronchodilator FEV1 after 12 weeks than did placebo (placebo group: 2246 mL [SD 768] at baseline vs 2261 mL [796] at week 12, change from baseline of 0 mL; benralizumab group: 2248 mL [606] vs 2310 mL [670], 70 mL). 44 (42%) patients in the benralizumab group had adverse events compared with 49 (47%) in the placebo group. The most common adverse events for both groups were nasopharyngitis (eight [8%] patients in each group) and upper respiratory tract infections (five [5%] patients in each group). Serious adverse events occurred in two (2%) patients each in the benralizumab (pancytopenia and a suicide attempt, both considered unrelated to treatment) and placebo (cervix carcinoma and colon adenoma) groups. INTERPRETATION: This study suggests that active and modifiable disease processes might be ongoing in patients with mild to moderate, persistent asthma receiving ICS. Although the lung function improvement observed does not warrant use of benralizumab in this population because it did not reach the minimum clinically important difference of 10%, further studies to assess this finding should be considered. FUNDING: AstraZeneca.
引用
- Ferguson GT, FitzGerald JM, Bleecker ER, et al. Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2017. PMID: 28545978. doi:10.1016/S2213-2600(17)30190-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。